Mateon Therapeutics, Inc.
MATN
MATN was delisted on the 7th of December, 2016.
24 hedge funds and large institutions have $1.57M invested in Mateon Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$741K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$559K |
| 3 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$82.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$42.8K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$36.2K |
Top Sellers
MATN Hedge Fund Activity: Q2 2016 in Review
24 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Mateon Therapeutics, Inc. (MATN) for Q2 2016, worth a combined $1.57M.
Buyers outnumbered sellers: 24 funds opened new MATN positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $741K.
- 24 institutional investors held Mateon Therapeutics, Inc. (MATN) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $1.57M of Mateon Therapeutics, Inc. stock for Q2 2016.
- 24 funds opened new Mateon Therapeutics, Inc. positions in Q2 2016 and 0 closed out, a net change of +24 holders.
- The largest Mateon Therapeutics, Inc. buyer in Q2 2016 was Renaissance Technologies, an estimated $741K added.
Based on aggregated 13F filings for Q2 2016.